We are live on ! Find out more
BLFS icon

BioLife Solutions

149 hedge funds and large institutions have $823M invested in BioLife Solutions in 2024 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 51 increasing their positions, 46 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,047% more call options, than puts

Call options by funds: $3.92M | Put options by funds: $342K

100% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 9

11% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 46

11% more capital invested

Capital invested by funds: $743M → $823M (+$79.8M)

6% more funds holding

Funds holding: 140149 (+9)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

3.5% less ownership

Funds ownership: 101.53%98.03% (-3.5%)

Holders
149
Holders Change
+9
Holders Change %
+6.43%
% of All Funds
2.15%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
18
Increased
51
Reduced
46
Closed
9
Calls
$3.92M
Puts
$342K
Net Calls
+$3.58M
Net Calls Change
+$357K

BLFS Hedge Fund Activity: Q1 2024 in Review

149 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in BioLife Solutions (BLFS) for Q1 2024, worth a combined $823M — up 11% from $743M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new BLFS positions and 9 closed out — a net gain of 9 holders — while 51 added to existing stakes and 46 trimmed.

The largest buyer was Cramer Rosenthal McGlynn, opening a new position worth an estimated $20.4M. The largest seller was Goldman Sachs, cutting an estimated $39.4M.

  • 149 institutional investors held BioLife Solutions (BLFS) as of Q1 2024, up from 140 in Q4 2023.
  • Funds reported $823M of BioLife Solutions stock for Q1 2024, up 11% quarter-over-quarter.
  • 18 funds opened new BioLife Solutions positions in Q1 2024 and 9 closed out, a net change of +9 holders.
  • The largest BioLife Solutions buyer in Q1 2024 was Cramer Rosenthal McGlynn, an estimated $20.4M added.
  • The largest BioLife Solutions seller in Q1 2024 was Goldman Sachs, an estimated $39.4M sold.

Based on aggregated 13F filings for Q1 2024.